scholarly journals SP717Sclerostin Is an Independent Risk Factor for All-cause Mortality in Older Kidney Transplant Recipients and Graft Loss in Younger Kidney Transplant Recipients

2019 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
Shufei Zeng ◽  
Torsten Slowinski ◽  
Wolfgang Pommer ◽  
Ahamed Hasan A. ◽  
Mohamed Gaballa M.s. ◽  
...  
Keyword(s):  
Risk Factor ◽  
Kidney Transplant ◽  
Independent Risk Factor ◽  
Graft Loss ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
All Cause Mortality

scholarly journals Sclerostin is an independent risk factor for all-cause mortality in kidney transplant recipients

2020 ◽  
Vol 24 (12) ◽  
pp. 1177-1183
Author(s):  
Shufei Zeng ◽  
Torsten Slowinski ◽  
Wolfgang Pommer ◽  
Ahmed A. Hasan ◽  
Mohamed M. S. Gaballa ◽  
...  
Keyword(s):  
Risk Factor ◽  
Renal Transplant ◽  
Kidney Transplant ◽  
Independent Risk Factor ◽  
Cox Regression ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Kaplan Meier ◽  
All Cause Mortality

Abstract Background Sclerostin is a hormone contributing to the bone-vascular wall cross talk and has been implicated in cardiovascular events and mortality in patients with chronic kidney disease (CKD). We analyzed the relationship between sclerostin and mortality in renal transplant recipients. Methods 600 stable renal transplant recipients (367men, 233 women) were followed for all-cause mortality for 3 years. Blood and urine samples for analysis and clinical data were collected at study entry. We performed Kaplan–Meier survival analysis and Cox regression models considering confounding factors such as age, eGFR, cold ischemia time, HbA1c, phosphate, calcium, and albumin. Optimal cut-off values for the Cox regression model were calculated based on ROC analysis. Results Sixty-five patients died during the observation period. Nonsurvivors (n = 65; sclerostin 57.31 ± 30.28 pmol/L) had higher plasma sclerostin levels than survivors (n = 535; sclerostin 47.52 ± 24.87 pmol/L) (p = 0.0036). Kaplan–Meier curve showed that baseline plasma sclerostin concentrations were associated with all-cause mortality in stable kidney transplant recipients (p = 0.0085, log-rank test). After multiple Cox regression analysis, plasma levels of sclerostin remained an independent predictor of all-cause mortality (hazard ratio, 1.011; 95% CI 1.002–1.020; p = 0.0137). Conclusions Baseline plasma sclerostin is an independent risk factor for all-cause mortality in patients after kidney transplantation.

High Ficolin-3 Level at the Time of Transplantation Is an Independent Risk Factor for Graft Loss in Kidney Transplant Recipients

2015 ◽  
Vol 99 (4) ◽  
pp. 791-796 ◽  
Author(s):  
Yuliya V. Smedbråten ◽  
Solbjørg Sagedal ◽  
Geir Mjøen ◽  
Anders Hartmann ◽  
Morten W. Fagerland ◽  
...  
Keyword(s):  
Risk Factor ◽  
Kidney Transplant ◽  
Independent Risk Factor ◽  
Graft Loss ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Percentage of Hypochromic Red Blood Cells is an Independent Risk Factor for Mortality in Kidney Transplant Recipients

2004 ◽  
Vol 4 (12) ◽  
pp. 2075-2081 ◽  
Author(s):  
Wolfgang C. Winkelmayer ◽  
Matthias Lorenz ◽  
Reinhard Kramar ◽  
Walter H. Horl ◽  
Gere Sunder-Plassmann
Keyword(s):  
Risk Factor ◽  
Red Blood Cells ◽  
Kidney Transplant ◽  
Blood Cells ◽  
Independent Risk Factor ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

P1798MYCOPHENOLIC ACID TROUGH CONCENTRATION AND DOSE ARE ASSOCIATED WITH HEMATOLOGIC ABNORMALITIES BUT NOT REJECTION IN KIDNEY TRANSPLANT RECIPIENTS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Hee-Yeon Jung ◽  
Sukyung Lee ◽  
Yena Jeon ◽  
Jeong-Hoon Lim ◽  
Ji-Young Choi ◽  
...  
Keyword(s):  
Risk Factor ◽  
Kidney Transplant ◽  
Trough Concentration ◽  
Independent Risk Factor ◽  
Mean Value ◽  
Fixed Dose ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Increased Risk ◽  
The Mean

Abstract Background and Aims Little is known regarding the safe fixed dose of mycophenolic acid (MPA) for preventing biopsy-proven acute rejection (BPAR) in kidney transplant recipients (KTRs). We investigated the correlation of MPA trough concentration (MPA C0) and dose with renal transplant outcomes and adverse events. Method This study included 79 consecutive KTRs who received MPA with tacrolimus (TAC) and corticosteroids. The MPA C0 of all the enrolled KTRs was measured, which was determined monthly by using particle-enhanced turbidimetric inhibition immunoassay for 12 months, and clinical data were collected at each time point. The clinical endpoints included BPAR, any cytopenia, and BK or cytomegalovirus infections. Results No differences in MPA C0 and dose were observed between KTRs with or without BPAR or viral infections under statistically comparable TAC concentrations. MPA C0 was significantly higher in patients with leukopenia (P = 0.021) and anemia (P = 0.002) compared with those without cytopenia. The MPA dose was significantly higher in patients with thrombocytopenia (P = 0.002) compared with those without thrombocytopenia. MPA C0 ≥ 3.5 µg/mL was an independent risk factor for leukopenia (adjusted odds ratio [AOR] 3.80, 95% confidence interval [CI] 1.24–11.64, P = 0.019) and anemia (AOR 5.90, 95% CI 1.27–27.51, P = 0.024). An MPA dose greater than the mean value of 1188.8 mg/day was an independent risk factor for thrombocytopenia (AOR 3.83, 95% CI 1.15–12.78, P = 0.029). However, an MPA dose less than the mean value of 1137.3 mg/day did not increase the risk of BPAR. Conclusion Either a higher MPA C0 or dose was associated with an increased risk of cytopenia, but neither a lower MPA C0 nor dose was associated with BPAR within the first year of transplantation. Hence, a reduced MPA dose with TAC and corticosteroids might be safe in terms of reducing hematologic abnormalities without causing rejection.

Sign in / Sign up

Export Citation Format

Share Document